Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies

Different viral agents are associated with an increased risk of more severe disease course and respiratory complications in immunocompromised patients.1–3 The recent outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) responsible for a severe acute respiratory syndrome (SARS) represents a source of concern for the management of patients with inflammatory rheumatic diseases. Lombardy is the region in Northern Italy with the highest incidence of COVID-19 cases, with more than 33,000 confirmed patients and 1250 requiring admission to the intensive care unit within 1 month. Since the first reports of COVID-19 cases in Italy, we have circulated a survey with a 2-week follow-up contact to patients with chronic arthritis treated with biological disease-modifying antirheumatic drugs (bDMARDs) or targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) followed up at our biological outpatient clinic in Pavia, Lombardy. The survey investigated the patients’ health conditions, the presence of contacts with subjects known to be affected by COVID-19 and management of the DMARDs during the first few weeks of pandemic. All patients had provided their informed consent for the use of personal and clinical data for scientific purposes, and no patient refused to participate.

During the first month, we have collected information on 320 patients (female 68%, mean age 55±14 years) treated with bDMARDs or tsDMARDs (57% with rheumatoid arthritis, 43% with spondyloarthritis, 52% treated with tumour necrosis factor inhibitors, 40% with other bDMARDs and 8% with tsDMARDs). As shown in table 1, four were confirmed cases of COVID-19 identified through rhinopharyngeal swabs. Another four patients reported symptoms which were highly suggestive of COVID-19. Five additional patients with reported certain contacts remained asymptomatic at the end of the 2-week observation period.

All patients with confirmed COVID-19 received at least one antibiotic course, and the hospitalised patient also received antiviral therapy and hydroxychloroquine. Overall, five patients were on previous stable treatment with hydroxychloroquine. All patients with symptoms of infection temporarily withdrew the bDMARD or tsDMARD at the time of symptom onset. To date,

### Table 1 Clinical characteristics of the patients with confirmed or suspected COVID-19

|                          | Confirmed COVID-19 | Clinical picture highly suggestive of COVID-19 | Contact with a known COVID-19 patient |
|--------------------------|--------------------|---------------------------------------------|--------------------------------------|
| Number of patients       | 4                  | 4                                           | 5                                    |
| Age (years) (mean±SD)    | 58±5               | 56±8                                        | 54±12                                |
| Female, n (%)            | 4 (100)            | 3 (75)                                      | 4 (80)                               |
| Comorbidities, n (%)     |                    |                                             |                                      |
| Hypertension             | 1 (25)             | 2 (50)                                      | 1 (20)                               |
| Diabetes                 | 0                  | 0                                           | 0                                    |
| Cardiovascular disease   | 0                  | 0                                           | 1 (20)                               |
| Other                    | 4 (100)            | 4 (100)                                     | 3 (60)                               |
| Smoking, n (%)           |                    |                                             |                                      |
| Active                   | 1 (25)             | 0                                           | 0                                    |
| Previous                 | 2 (50)             | 3 (75)                                      | 1 (20)                               |
| Rheumatological diagnosis|                    |                                             |                                      |
| RA, n (%)                | 3 (75)             | 3 (75)                                      | 5 (100)                              |
| SpA/PA, n (%)            | 1 (25)             | 1* (25)                                     | 0                                    |
| Rheumatological treatment, n (%) |
| bDMARD                   |                    |                                             |                                      |
| Adalimumab               | 0                  | 0                                           | 1 (20)                               |
| Etanercept               | 2 (50)             | 2 (50)                                      | 0                                    |
| Abatacept                | 1 (25)             | 1 (25)                                      | 0                                    |
| Tocilizumab              | 0                  | 0                                           | 1 (20)                               |
| tsDMARD                  |                    |                                             |                                      |
| Tofacitinib              | 1 (25)             | 0                                           | 1 (20)                               |
| Baricitinib              | 0                  | 1 (25)                                      | 2 (40)                               |
| Concomitant csDMARD      |                    |                                             |                                      |
| Methotrexate             | 2 (50)             | 1 (25)                                      | 3 (60)                               |
| Leflunomide              | 1 (25)             | 0                                           | 1 (20)                               |
| Sulfasalazine            | 0                  | 1 (25)                                      | 0                                    |
| Concomitant hydroxychloroquine | 1 (25) | 2 (50)                                      | 2 (40)                               |
| Low-dose glucocorticoids*| 2 (50)             | 2 (50)                                      | 2 (40)                               |
| Known contact with COVID-19 | 0                  | 1 (25)                                      | 5 (100)                              |
| Symptoms, n (%)          |                    |                                             |                                      |
| Fever                    | 4 (100)            | 1 (25)                                      | 0                                    |
| Non-productive cough     | 3 (75)             | 2 (50)                                      | 0                                    |
| Sputum production        | 1 (25)             | 0                                           | 0                                    |
| Rhinorhoea               | 2 (50)             | 1 (25)                                      | 0                                    |
| Sore throat              | 0                  | 0                                           | 0                                    |
| Fatigue                  | 4 (100)            | 2 (50)                                      | 0                                    |
| Myalgia                  | 2 (50)             | 1 (25)                                      | 0                                    |
| Arthralgia               | 1 (25)             | 1 (25)                                      | 0                                    |
| Anosmia/dysgeusia        | 3 (75)             | 3 (75)                                      | 0                                    |
| Dyspnoea at rest         | 1 (25)             | 0                                           | 0                                    |
| Dyspnoea on exertion     | 2 (50)             | 1 (25)                                      | 0                                    |
| Headache                 | 2 (50)             | 0                                           | 0                                    |
| Diarrhoea                | 1 (25)             | 0                                           | 0                                    |
| Nausea/vomiting          | 0                  | 0                                           | 0                                    |
| Chest X-ray performed    | 4 (100)            | 0†                                          | 0                                    |
| Chest X-ray pathological findings | 0 | 0 | 0 |
| Hospital admission       | 1 (25)             | 0                                           | 0                                    |

*Glucocorticoids 5 mg/day prednisone equivalent.
†Subject to home quarantine.

bDMARD: biological disease-modifying antirheumatic drug; COVID-19, coronavirus disease 2019; csDMARD, conventional synthetic disease-modifying antirheumatic drug; PA, psoriatic arthritis; RA, rheumatoid arthritis; SpA, spondyloarthritis; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.
there have been no significant relapses of the rheumatic disease. None of the patients with a confirmed diagnosis of COVID-19 or with a highly suggestive clinical picture developed severe respiratory complications or died. Only one patient, aged 65, required admission to hospital and low-flow oxygen supplementation for a few days.

Our findings do not allow any conclusions on the incidence rate of SARS-CoV-2 infection in patients with rheumatic diseases, nor on the overall outcome of immunocompromised patients affected by COVID-19. A high level of vigilance and strict follow-up should be maintained on these patients, including the exclusion of superimposed infections. However, our preliminary experience shows that patients with chronic arthritis treated with bDMARDs or tsDMARDs do not seem to be at increased risk of respiratory or life-threatening complications from SARS-CoV-2 compared with the general population.

These findings are not surprising as the severe respiratory complications caused by coronaviruses are thought to be driven by the aberrant inflammatory and cytokine response perpetuated by the host immune system. During different coronavirus outbreaks, such as SARS and Middle East respiratory syndrome, there has been no increased mortality reported in patients undergoing immunosuppression for organ transplantation, cancer or autoimmune diseases. Accordingly, among 700 patients admitted for severe COVID-19 at our hospital (a referral centre for SARS-CoV-2 infection) during last month, none was receiving bDMARDs or tsDMARDs.

Although continuous surveillance of patients with rheumatic diseases receiving immunosuppressive drugs is warranted, these data can support rheumatologists for the management and counselling of their patients, avoiding the unjustifiable preventive withdrawal of DMARDs, which could lead to an increased risk of relapses and morbidity from the chronic rheumatological condition.

Sara Monti, Silvia Balduzzi, Paolo Delvino, Elisa Bellis, Verdana Serena Quadrelli, Carlo Maurizio Montecucco

Rheumatology Department, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
Rheumatology Department, IRCCS Policlinico San Matteo, Pavia, Italy
Rheumatology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Correspondence to Dr Sara Monti, Rheumatology, IRCCS Fondazione Policlinico S Matteo, Pavia 27100, Italy; sara.saramonti@gmail.com

Handling editor Josef S Smolen

Contributors SM and CM contributed to the design of the project interpretation and analysis of the data, and writing of the manuscript. SB, PD, EB and VSQ contributed to the collection of data, interpretation and analysis of the data, and review of the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

OPEN ACCESS

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite Monti S, Balduzzi S, Delvino P, et al. Ann Rheum Dis 2020;79:667–668.

Received 26 March 2020
Accepted 27 March 2020
Published Online First 2 April 2020

Ann Rheum Dis 2020;79:667–668. doi:10.1136/annrheumdis-2020-217424

ORCID iD
Sara Monti http://orcid.org/0000-0002-1800-6772

REFERENCES

1 Memoli MJ, Athota R, Reed S, et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis 2014;58:214–24.
2 Noreña I, Fernández-Ruiz M, Aguado JM. Viral infections in the biologic therapy era. Expert Rev Anti Infect Ther 2018;16:781–91.
3 D’Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic. Liver Transpl 2020. doi:10.1002/lt.25756
4 Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ 2020;27:382.
5 Hui DS, Achar EI, Kim YJ, et al. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis 2018;18:e217–27.
No additional risk from COVID-19 for people with rheumatic diseases taking biologics and JAK inhibitors

There is no need for withdrawal of DMARDs during the COVID-19 pandemic.

INTRODUCTION
COVID-19 is caused by a new type of coronavirus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). It was declared a pandemic by the World Health Organization on 11 March 2020. COVID-19 has forced people to change their behaviours to try to limit the spread of infection.

Some people with rheumatic diseases are more likely to get infections. Some people are also more prone to complications when they get an infection. This is partly because of their underlying disease, and partly because some medicines used to treat rheumatic diseases work by suppressing the immune system.

WHAT DID THE AUTHORS HOPE TO FIND?
The authors wanted to see how the COVID-19 pandemic affected people with rheumatic diseases.

WHO WAS STUDIED?
The study looked at 320 people with rheumatic diseases being treated in Lombardy, Italy. Around two-thirds were female, with an average age of 55 years. 57% had rheumatoid arthritis, while 43% had spondyloarthritis. Most of the people taking part were receiving biologics (abatacept, adalimumab, etanercept, tocilizumab). Around 1 in 10 were receiving Janus kinase (JAK) inhibitors (baricitinib, tofacitinib).

HOW WAS THE STUDY CONDUCTED?
A survey was sent to people with rheumatic diseases, with another follow-up survey after 2 weeks. People were asked to report their health conditions, whether they had been in contact with anyone diagnosed with COVID-19, and how the pandemic had affected their attitude towards, and management of their rheumatic disease. The authors also looked at medical records, and reports from other clinics, in addition to the findings from the surveys.

WHAT WAS THE MAIN FINDING?
The main finding was that people with rheumatic diseases who are diagnosed with COVID-19 do not seem to have an increased risk of complications compared to the general population. The information suggests that biologic and JAK inhibitor medicines do not increase the risk of complications and should continue to be used to manage rheumatic diseases. However, caution is still warranted as these medicines work by suppressing the immune system, and people should continue to be closely monitored by their healthcare teams.

ARE THESE FINDINGS NEW?
Yes. At the time this report was published, there was limited information about COVID-19 in people with rheumatic diseases. This was the first paper to report that people with rheumatic diseases receiving biologics or JAK inhibitors who are diagnosed with COVID-19 have a similar level of risk of complications to that of the general population. Since this report was published, other research groups in different countries have found similar results,1,2 and many comments have supported the results.3-6 At the time this article was published, the largest study in people with rheumatic diseases and confirmed or suspected COVID-19 was 86 cases in New York City in the United States, where 72% of people treated with biologics or JAK inhibitors had similar rates of being admitted into hospital or dying from COVID-19, to that of the general population.2

WHAT ARE THE LIMITATIONS OF THIS STUDY?
The main limitation is that this study was quite small, with only 320 people from one part of Italy.
WHAT DO THE AUTHORS PLAN TO DO WITH THIS INFORMATION?
Information is being collected in national and international registries, such as the Italian Society of Rheumatology sponsored registry (COVID-19-RMD), or the European EULAR-COVID-19 Database. The data collected will help to work out what impact COVID-19 has on people with rheumatic diseases.7,8

WHAT DOES THIS MEAN FOR ME?
If you are taking a biologic or JAK inhibitor medicine for your rheumatic disease, these results suggest that you are not at higher risk of complications from COVID-19, and there is no need to stop taking your medicine.

If you are concerned about the risk of taking your medicine during the pandemic, you should speak to your doctor. It is important that you do not stop taking your medicine by yourself, as this could make your rheumatic disease worse.

Protect yourself from COVID-19 by following the advice of the government in your country, including washing your hands regularly, avoiding touching your face, and following social distancing rules.

REFERENCES
1. Emmi G, et al. SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmun Rev 2020;102575. doi:10.1016/j.autrev.2020.102575.
2. Haberman R, et al. Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York. N Engl J Med 2020. doi:10.1056/NEJMc2009567.
3. Monti S & Montecucco C. Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: ‘Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumonia’ by Guilpain et al. Ann Rheum Dis 2020 Apr 30.
4. Monti S & Montecucco C. The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: ‘Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology practitioners from India’ by Gupta et al and ‘Antirheumatic agents in covid-19: is IL-6 the right target?’ by Capechi et al. Ann Rheum Dis 2020 Apr 27.
5. Monti S & Montecucco C. Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: ‘Does hydroxychloroquine prevent the transmission of COVID-19?’ by Heldwein and Calado and ‘SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment’ by Joob and Wiwanitkit. Ann Rheum Dis 2020 Apr 23.
6. Favalli EG, et al. What is the true incidence of COVID-19 in patients with rheumatic diseases? Ann Rheum Dis 2020. pii:annrheumdis-2020-217615.
7. McInnes IB. COVID-19 and rheumatology: first steps towards a different future? Ann Rheum Dis 2020;79(5):551552. doi:10.1136/annrheumdis-2020-217494.
8. Gianfrancesco MA, et al. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol 2020. doi:10.1016/S2665-9913(20)30093-3.

Disclaimer: This is a summary of a scientific article written by a medical professional (“the Original Article”). The Summary is written to assist non medically trained readers to understand general points of the Original Article. It is supplied “as is” without any warranty. You should note that the Original Article (and Summary) may not be fully relevant nor accurate as medical science is constantly changing and errors can occur. It is therefore very important that readers not rely on the content in the Summary and consult their medical professionals for all aspects of their health care and only rely on the Summary if directed to do so by their medical professional. Please view our full Website Terms and Conditions. http://www.bmj.com/company/legal-information/

Date prepared: May 2020

Summary based on research article published on: 2 April 2020

From: Monti S, et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020;79:667–668. doi:10.1136/annrheumdis-2020-217424

Copyright © 2020 BMJ Publishing Group Ltd & European League Against Rheumatism. Medical professionals may print copies for their and their patients and students non commercial use. Other individuals may print a single copy for their personal, non commercial use. For other uses please contact our Rights and Licensing Team.